NTDT Patient Management
10 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to Lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the primary goal of luspatercept in treating anemia in NTDT?

  • To increase hepcidin production
  • To decrease the transfusion of red blood cells (correct)
  • To reduce iron overload
  • To increase the lifespan of erythroid cells

What was the primary endpoint met in the BEYOND trial?

  • Reduction in iron overload
  • Decrease in tiredness and weakness
  • Increase in hemoglobin level of ≥2 g/dL
  • Increase in hemoglobin level of ≥1 g/dL (correct)

Which of the following is NOT an approach to treating anemia in NTDT?

  • Stimulating hepcidin production
  • Transfusing red blood cells (correct)
  • Inhibiting ferroportin
  • Activating pyruvate kinase

What was the response rate in the luspatercept group in the BEYOND trial?

<p>77% (B)</p> Signup and view all the answers

What is the name of the phase 2 randomized placebo-controlled trial evaluating the efficacy and safety of luspatercept?

<p>BEYOND trial (C)</p> Signup and view all the answers

What is the name of the ferroportin inhibitor mentioned in the text?

<p>VIT-276322 (B)</p> Signup and view all the answers

What is the name of the pyruvate kinase activators mentioned in the text?

<p>Mitapivat and Etavopivat (D)</p> Signup and view all the answers

In which year was the application for regulatory approval of luspatercept withdrawn in the United States?

<p>2022 (C)</p> Signup and view all the answers

What is the name of the antisense oligonucleotide mentioned in the text?

<p>TMPRSS6LRx (D)</p> Signup and view all the answers

What is the name of the small interfering ribonucleic acid mentioned in the text?

<p>SLN124 (C)</p> Signup and view all the answers

More Like This

Use Quizgecko on...
Browser
Browser